Leipzig Messe, Germany. Photograph/Labiotech

Atriva Therapeutics’ mission is to develop an antiviral remedy platform towards extreme respiratory and systemic ailments with a excessive unmet medical want induced by RNA viruses, e.g., influenza and COVID-19. 

The clinical-stage biopharmaceutical firm is pioneering the event of host-targeting antiviral therapies, making growth of viral resistance unlikely, and thereby considerably contributing to pandemic preparedness. 

The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that goals to inhibit viral replication and to favorably modulate the physique’s immune response to RNA viruses. 

Atriva Therapeutics was based in 2015 in Germany by a workforce of scientists in viral analysis and trade specialists and is predicated in Tübingen, Frankfurt, and Martinsried (IZB, close to Munich), Germany.

We spoke with founder and CEO, Rainer Lichtenberger at BIO-Europe, in Leipzig, Germany.

Lichtenberger is ready to retire in 2023, and his successor has been introduced as Christian Pangratz.

Source link